Last edition
News about "Immunology therapies"
Bristol Myers Squibb and Hengrui Pharma collaborated to jointly develop 13 early-stage programmes across oncology, haematology and immunology, with a potential deal value of up to USD 15.2 billion.
Immunology Therapies | 13/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members